Natixis Advisors L.P. lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 15.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 98,060 shares of the biopharmaceutical company’s stock after purchasing an additional 13,175 shares during the quarter. Natixis Advisors L.P.’s holdings in Gilead Sciences were worth $6,625,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Advisors Preferred LLC bought a new position in shares of Gilead Sciences in the 2nd quarter worth about $26,000. Weaver Consulting Group purchased a new stake in shares of Gilead Sciences in the 1st quarter worth approximately $34,000. Trustcore Financial Services LLC bought a new position in Gilead Sciences during the 1st quarter valued at approximately $34,000. Legacy Advisors LLC bought a new position in Gilead Sciences during the 2nd quarter valued at approximately $37,000. Finally, Evolution Wealth Advisors LLC purchased a new position in Gilead Sciences during the second quarter valued at $46,000. 79.89% of the stock is currently owned by institutional investors.

NASDAQ:GILD traded up $0.23 during trading hours on Wednesday, reaching $67.31. The company had a trading volume of 580,925 shares, compared to its average volume of 5,460,585. The company has a current ratio of 3.76, a quick ratio of 3.67 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 52 week low of $60.32 and a 52 week high of $79.61. The firm has a market cap of $84.00 billion, a price-to-earnings ratio of 10.95, a PEG ratio of 3.15 and a beta of 1.10. The firm’s 50 day moving average price is $64.48 and its 200-day moving average price is $65.43.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.14. The business had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.54 billion. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The company’s quarterly revenue was down 2.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.91 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 6.66 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, September 12th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.74%. Gilead Sciences’s dividend payout ratio is currently 40.98%.

In related news, Director Olsen Per Wold sold 4,908 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $63.91, for a total value of $313,670.28. Following the transaction, the director now owns 102,762 shares of the company’s stock, valued at $6,567,519.42. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Brett A. Pletcher sold 5,816 shares of the firm’s stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total transaction of $399,850.00. Following the completion of the transaction, the executive vice president now directly owns 27,198 shares in the company, valued at approximately $1,869,862.50. The disclosure for this sale can be found here. Insiders have sold a total of 18,532 shares of company stock valued at $1,221,149 in the last ninety days. Insiders own 0.20% of the company’s stock.

Several research firms have commented on GILD. Cantor Fitzgerald set a $88.00 target price on Gilead Sciences and gave the stock a “buy” rating in a report on Monday, July 15th. ValuEngine downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, September 4th. Morgan Stanley set a $82.00 price target on Gilead Sciences and gave the stock a “hold” rating in a research report on Monday, July 15th. Evercore ISI reiterated a “buy” rating on shares of Gilead Sciences in a research note on Friday, May 17th. Finally, BidaskClub cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $82.24.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: What are the benefits of momentum investing?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.